Login
$XNCR
$35.40 -$1.69 (4.56%) Live

$XNCR SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G
12 Nov 2026 Form 4: Cornelissen Bart Jan, SR. VICE PRESIDENT & CFO

Sold 10,100 shares ($402K)

12 Nov 2026 Form 4: Ranieri Richard J, Director

Received 75,755 shares by exercise or conversion ($1.43M) · Sold 81,252 shares ($3.19M)

12 Nov 2026 144
10 Nov 2026 144
06 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

-- Updated results for XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma and outline of plans for potential registration-enabling development presented during ESMO --

30 Oct 2026 SCHEDULE 13G/A
27 Oct 2026 SCHEDULE 13G/A
26 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

® Designing Proteins Delivering Medicines Updated Results from Dose Expansion Cohorts in the Phase 1 Study of XmAb819 October 26, 2026

05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

-- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned --

31 Jul 2026 SCHEDULE 13G
29 Jul 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties --

08 Jul 2026 Form 4: Feigal Ellen, Director

Received 10,302 shares as a grant or award · Granted 20,604 Stock Option (Right to Buy)

08 Jul 2026 Form 4: Gorman Kevin Charles, Director

Received 10,302 shares as a grant or award · Granted 20,604 Stock Option (Right to Buy)

08 Jul 2026 Form 4: Gustafson Kurt A, Director

Received 10,302 shares as a grant or award · Granted 20,604 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support